Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Acquires $52,767.00 in Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal M. Patel purchased 53,300 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the purchase, the chief executive officer now owns 10,117,788 shares in the company, valued at $10,016,610.12. This trade represents a 0.53 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Nautilus Biotechnology Stock Performance

Shares of NAUT stock traded down $0.01 during trading hours on Friday, reaching $0.99. The company had a trading volume of 366,513 shares, compared to its average volume of 93,933. Nautilus Biotechnology, Inc. has a one year low of $0.93 and a one year high of $3.09. The business has a fifty day moving average price of $1.55 and a 200-day moving average price of $2.12. The firm has a market cap of $124.89 million, a PE ratio of -1.77 and a beta of 1.25.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Nautilus Biotechnology by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,142,542 shares of the company’s stock valued at $1,920,000 after purchasing an additional 7,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Nautilus Biotechnology by 11.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 770,353 shares of the company’s stock worth $1,294,000 after acquiring an additional 78,367 shares during the last quarter. Wexford Capital LP boosted its stake in shares of Nautilus Biotechnology by 42.4% during the fourth quarter. Wexford Capital LP now owns 325,239 shares of the company’s stock valued at $546,000 after purchasing an additional 96,889 shares during the period. Renaissance Technologies LLC raised its stake in shares of Nautilus Biotechnology by 61.7% during the fourth quarter. Renaissance Technologies LLC now owns 250,221 shares of the company’s stock valued at $420,000 after acquiring an additional 95,521 shares in the last quarter. Finally, Citadel Advisors LLC grew its position in shares of Nautilus Biotechnology by 171.4% during the 4th quarter. Citadel Advisors LLC now owns 220,220 shares of the company’s stock worth $370,000 after buying an additional 139,081 shares in the last quarter. Institutional investors own 50.71% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Guggenheim set a $2.50 price target on shares of Nautilus Biotechnology in a report on Friday, February 28th. The Goldman Sachs Group downgraded Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $2.25 to $1.75 in a research report on Thursday, December 5th.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.